idea-016 · vet · US
For single-use, in-clinic instillation and aspiration of sterile isotonic; irrigation fluid in the external ear canal of dogs undergoing ear cleaning or ear flushing; as part of the management of otitis externa, performed by or under the direction of a; licensed veterinarian in a sedated or anaesthetised patient following otoscopic examination; not for the delivery of medicated or therapeutic solutions, not for use in the middle ear; beyond fluid recovered through an already-accessible tympanic defect, and not for home or; owner use.
Still being built — 6 of 8 wrap criteria met; nothing for you to decide yet. No department has been asked. 2 of 37 claims verified, 1 refuted. Nobody has yet written down what it rests on.
A hand-held, single-use, coaxial dual-lumen catheter for the canine external ear canal. The outer body carries graduated depth markings and an adjustable depth-limiting collar so the operator sets and holds a known insertion depth. The inner irrigation lumen is fed from a standard syringe or IV fluid line through an inline mechanical pressure-relief valve that vents above a fixed cracking pressure, capping delivered irrigation pressure regardless of how hard the operator pushes the plunger. The outer aspiration lumen connects to ordinary clinic suction through a volume-graduated inline trap, so the volume instilled and the volume recovered can be read off and compared as a procedural endpoint ("the canal and any accessible bulla fluid are cleared") rather than judged by feel. Soft, tapered, atraumatic tip; a size-matched tip family across canal diameters. No energy source, no software, no active electronics.
In the mechanism, as the candidate file states it — the plain-language paragraph in ## Wrap has not been written yet. Domain: none linked
No business case yet, so nothing here says who writes the cheque. /business-case idea-016 builds one.
What this idea rests on that is not yet known, in the order this idea's own decision queue puts it: worst if false first, cheapest to settle first inside that. The first row is open; open any other for what would settle it.
This idea is unassessed, so nobody has yet named the few things it rests on. Until then, the gaps below are the rubric factors that are unscored or carry an open question. /assess idea-016 replaces this list with the real one.
Why it scored what it did: Claims 1-2: if they hold, an animal-only intended use has no US premarket submission of any kind — 807.65(b) exempts veterinary-only manufacturers and 807.20(a)/807.81(a)/814.1(a) attach only to human-use devices. Not 5: claim 3unconfirmed's…the rest of this reasoning
animal-drug boundary is the live risk in this lane and is itself unverified, and the frontmatter's part-874 row is NOT LIVE and was not scored.
What would settle it: Full-text eCFR read of 807.65(b), 807.20(a), 807.81(a), 814.1(a) against this intended-use statement, plus 21 CFR (Title 21 of the Code of Federal Regulations) part 514 and 21 U.S.C. 360b for the claim-3 boundary — free, about an hour.
Why it scored what it did: Claims 14, 15: no CPT (Current Procedural Terminology), no HCPCS (Healthcare Common Procedure Coding System), no LCD (local coverage determination)/NCD and no third-party payer exists for a veterinary procedure; the practice buys the consumable and the owner pays out of pocket, with pet insurance at a low single-digit share of US pets. Scored as…the rest of this reasoning
a floor, not as "pending research" — there is no code to find. Not 0: a functioning cash-pay channel through practice purchasing is asserted.
What would settle it: Negative CPT/HCPCS/coverage lookups confirm the absence at no cost. The evidence that would actually move this is the primary NAPHIA State of the Industry report and a veterinary practice-management price list showing what an ear-flush…the rest of this gap analysis
line item bears — one free, one licensed.
Why it scored what it did: Claims 5, 6, 7 give a population leg (Banfield-reported 15.8% otitis externa, corroborated by a 5-20% practice range) and claim 10unconfirmed an 80-90M US dog base; claims 11 (20-40% flushed in-clinic) and 12 ($12-25/kit) are stated by the Generator…the rest of this reasoning
as assumptions with no source. If all four held, the implied US procedure revenue clears the 2/5 floor but not comfortably. claim 13unconfirmed flags every one of these as connector-unreachable.
What would settle it: The primary Banfield State of Pet Health report for the population leg (free, one document), plus a licensed veterinary practice-management dataset (e.g. VetSuccess/Vetsource) for flush-procedure share and consumable pricing — licensed,…the rest of this gap analysis
real cost, human-attached.
Why it scored what it did: Claims 18-19: no patent search of any kind was performed and no number, family, assignee or expiry is named; claim 19unconfirmed is explicitly an assumption and does not raise this score. claim 17unconfirmed removes the lane's usual advantage here — 35 U.S.C.…the rest of this reasoning
271(a) reaches making/using/selling without reference to species, so the veterinary exemption buys nothing on this factor. Not 0: nothing is known to block, either.
What would settle it: A USPTO (United States Patent and Trademark Office)/Google Patents search against the named targets — OtoPet-USA, Nupur Technologies, Stryker InterPulse, and ENT irrigation-suction handpieces — a few hours of analyst time, free. A clearance opinion needs outside counsel and real…the rest of this gap analysis
money.
Why it scored what it did: claim 21unconfirmed: no technical barrier identified that would stop an existing veterinary-consumables manufacturer from copying the device once shipped; all three proposed levers (bench dataset, tip family, distribution) are unquantified and…the rest of this reasoning
unestablished.
What would settle it: The bench dataset in claim 21unconfirmed(a) is the only lever that could become defensible, and it does not exist yet. Short of that, a trademark/design-registration and distributor-channel scan of veterinary consumables suppliers — free desk…the rest of this gap analysis
research, a few hours.
Why it scored what it did: claim 8unconfirmed says the failure modes the device targets (tympanic rupture, ototoxicity, vestibular signs) are real and documented, and the hardware is passive — no energy, no software. Held down by claim 9unconfirmed, a named hole: no published canine…the rest of this reasoning
tympanic rupture pressure threshold was found, so the relief valve's cracking pressure has no numerical basis; and by claim 24unconfirmed, the instilled-vs-recovered endpoint is an untested hypothesis.
What would settle it: A cadaveric canine temporal-bone study establishing the irrigation-pressure rupture threshold (claim 9unconfirmed) — a funded bench programme, weeks and real money. claim 8unconfirmed's failure modes are settleable free via PubMed.
Why it scored what it did: Inferred from claims 1-2 (no premarket submission to fund or wait on) and the mechanism's simplicity as a moulded single-use disposable. Held to 3 because claims 9 and 24 put a bench programme ahead of launch, and no claim in this file…the rest of this reasoning
gives an actual build cost or time-to-first-dollar.
What would settle it: Contract-manufacturer quotes for a moulded dual-lumen disposable plus a costed bench-programme plan — a human-attached estimate, no fixed price.
Why it scored what it did: claim 20unconfirmed names OtoPet-USA's veterinary Earigator console and Nupur's human system and found no single-use pressure-limited dual-lumen catheter — but claim 20unconfirmed itself says that absence is only a missed web-search hit and must not be scored…the rest of this reasoning
as white space. claim 16unconfirmed's entrenched red rubber catheter and syringe is the real competitor, and it is nearly free.
What would settle it: OtoPet-USA and veterinary distributor catalogue pricing for the console (free). A primary practice survey of current ear-flush technique would settle claim 16unconfirmed's share question — real money and weeks.
Why it scored what it did: none — no numbered claim in this file addresses fit against the current portfolio. The prose note that idea-002, idea-007 and idea-012 share the veterinary regulatory lever is not written as a claim and was not scored.
What would settle it: Not connector-checkable — a Tier 3 human portfolio judgement, free but requiring a human decision.
Seven chairs, each answering from its own field. The verdict, and the first condition it set.
Not convened. No department has stated a position on this idea yet — a normal state, not a defect. /round-table idea-016 asks all seven.
Only verified counts toward a score. A low count is usually a statement about the tooling — an absent data file, an unset key — rather than about the idea.
1 claim(s) the Verifier found to be false — a refuted claim is a finding, and the loop owes each one an answer.
No cheapest next test written yet — /wrap idea-016 names one.
Nothing is waiting on a decision. The next move above is work, not a choice.
Only verified counts toward a score. A low count is usually a statement about the tooling (an absent data file, an unset key) rather than about the idea.
No gate check recorded yet.
To finish it:
domains: — run /research## Wrap section with a **Cheapest next test:** lineNo human review is recorded. Shortlisting, legal and clinical sign-off and capital allocation are Tier 3: no agent in this repo makes or simulates one.
Runs only after a human shortlists the idea.
No loop record: nobody has written down what this idea rests on or convened a department on it. That is a normal state, not a defect. /front-end-loop idea-016 opens one.
Nobody has yet written down what this idea rests on and what it would cost to be wrong. Unassessed is a state, not a low score. /assess idea-016 adds it.
Click any step to see what it holds for this idea. donecurrentloopinghuman only
## Wrap section, as writtenThis candidate has no ## Wrap section yet. Run /wrap idea-016 to write one.
| Factor | Score | Why | What would settle it |
|---|---|---|---|
| Regulatory pathway | 4 | Claims 1-2: if they hold, an animal-only intended use has no US premarket submission of any kind — 807.65(b) exempts veterinary-only manufacturers and 807.20(a)/807.81(a)/814.1(a) attach only to human-use devices. Not 5: claim 3unconfirmed's…the rest of this reasoninganimal-drug boundary is the live risk in this lane and is itself unverified, and the frontmatter's part-874 row is NOT LIVE and was not scored. | Full-text eCFR read of 807.65(b), 807.20(a), 807.81(a), 814.1(a) against this intended-use statement, plus 21 CFR part 514 and 21 U.S.C. 360b for the claim-3 boundary — free, about an hour. |
| Reimbursement pathway | 1 | Claims 14, 15: no CPT, no HCPCS, no LCD/NCD and no third-party payer exists for a veterinary procedure; the practice buys the consumable and the owner pays out of pocket, with pet insurance at a low single-digit share of US pets. Scored as…the rest of this reasoninga floor, not as "pending research" — there is no code to find. Not 0: a functioning cash-pay channel through practice purchasing is asserted. | Negative CPT/HCPCS/coverage lookups confirm the absence at no cost. The evidence that would actually move this is the primary NAPHIA State of the Industry report and a veterinary practice-management price list showing what an ear-flush…the rest of this gap analysisline item bears — one free, one licensed. |
| TAM | 2 | Claims 5, 6, 7 give a population leg (Banfield-reported 15.8% otitis externa, corroborated by a 5-20% practice range) and claim 10unconfirmed an 80-90M US dog base; claims 11 (20-40% flushed in-clinic) and 12 ($12-25/kit) are stated by the Generator…the rest of this reasoningas assumptions with no source. If all four held, the implied US procedure revenue clears the 2/5 floor but not comfortably. claim 13unconfirmed flags every one of these as connector-unreachable. | The primary Banfield State of Pet Health report for the population leg (free, one document), plus a licensed veterinary practice-management dataset (e.g. VetSuccess/Vetsource) for flush-procedure share and consumable pricing — licensed,…the rest of this gap analysisreal cost, human-attached. |
| FTO / IP | 1 | Claims 18-19: no patent search of any kind was performed and no number, family, assignee or expiry is named; claim 19unconfirmed is explicitly an assumption and does not raise this score. claim 17unconfirmed removes the lane's usual advantage here — 35 U.S.C.…the rest of this reasoning271(a) reaches making/using/selling without reference to species, so the veterinary exemption buys nothing on this factor. Not 0: nothing is known to block, either. | A USPTO/Google Patents search against the named targets — OtoPet-USA, Nupur Technologies, Stryker InterPulse, and ENT irrigation-suction handpieces — a few hours of analyst time, free. A clearance opinion needs outside counsel and real…the rest of this gap analysismoney. |
| Moat / defensibility | 1 | claim 21unconfirmed: no technical barrier identified that would stop an existing veterinary-consumables manufacturer from copying the device once shipped; all three proposed levers (bench dataset, tip family, distribution) are unquantified and…the rest of this reasoningunestablished. | The bench dataset in claim 21unconfirmed(a) is the only lever that could become defensible, and it does not exist yet. Short of that, a trademark/design-registration and distributor-channel scan of veterinary consumables suppliers — free desk…the rest of this gap analysisresearch, a few hours. |
| Mechanism & clinical risk | 2 | claim 8unconfirmed says the failure modes the device targets (tympanic rupture, ototoxicity, vestibular signs) are real and documented, and the hardware is passive — no energy, no software. Held down by claim 9unconfirmed, a named hole: no published canine…the rest of this reasoningtympanic rupture pressure threshold was found, so the relief valve's cracking pressure has no numerical basis; and by claim 24unconfirmed, the instilled-vs-recovered endpoint is an untested hypothesis. | A cadaveric canine temporal-bone study establishing the irrigation-pressure rupture threshold (claim 9unconfirmed) — a funded bench programme, weeks and real money. claim 8unconfirmed's failure modes are settleable free via PubMed. |
| Capital intensity & time-to-revenue | 3 | Inferred from claims 1-2 (no premarket submission to fund or wait on) and the mechanism's simplicity as a moulded single-use disposable. Held to 3 because claims 9 and 24 put a bench programme ahead of launch, and no claim in this file…the rest of this reasoninggives an actual build cost or time-to-first-dollar. | Contract-manufacturer quotes for a moulded dual-lumen disposable plus a costed bench-programme plan — a human-attached estimate, no fixed price. |
| Competitive intensity | 3 | claim 20unconfirmed names OtoPet-USA's veterinary Earigator console and Nupur's human system and found no single-use pressure-limited dual-lumen catheter — but claim 20unconfirmed itself says that absence is only a missed web-search hit and must not be scored…the rest of this reasoningas white space. claim 16unconfirmed's entrenched red rubber catheter and syringe is the real competitor, and it is nearly free. | OtoPet-USA and veterinary distributor catalogue pricing for the console (free). A primary practice survey of current ear-flush technique would settle claim 16unconfirmed's share question — real money and weeks. |
| Strategic fit & portfolio balance | — | none — no numbered claim in this file addresses fit against the current portfolio. The prose note that idea-002, idea-007 and idea-012 share the veterinary regulatory lever is not written as a claim and was not scored. | Not connector-checkable — a Tier 3 human portfolio judgement, free but requiring a human decision. |
To finish this packet:
domains: — run /research## Wrap section with a **Cheapest next test:** lineSource file: knowledge-base/candidates/idea-016.md
Nothing on this page is a recommendation. Shortlist review, legal and clinical sign-off and capital allocation are human-only decisions, and no agent in this repo may make or simulate one. This is a compilation of what the candidate file says.
_shared/plain-language.md